Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2014

View Archived Issues

One Lambda licenses HLA primer technology from GenoDive Pharma

NIAID grant supports TB drug development at Microbiotix

Yabao and Lilly partner on glucokinase activator in China

Once-daily tofacitinib shows bioequivalence for the immediate-release formulation

Mariel Therapeutics to acquire Stryker's BMP-7 assets

Arrien Pharmaceuticals prepares new SIK-2 inhibitors

Researchers at AbbVie synthesize novel PKC inhibitors for autoimmune diseases

New orexin receptor antagonists reported by Taisho Pharmaceutical

Takeda Pharmaceutical synthesizes new CH24H inhibitors

Enrollment begins in phase I trial of TPI-287 in rare tauopathy diseases

Genmab achieves third milestone in daratumumab collaboration

Novel lipidated NMU analogues with promise for suppressing food intake in vivo

Cellceutix patents novel agents for bacterial and other infections

Patient enrollment completed in phase II trial of carboplatin, paclitaxel and Reolysin

Biotie awarded Michael J. Fox Foundation grant for a clinical study of SYN-120

Merck & Co. discloses new BACE inhibitors for Alzheimer's disease

Portola Pharmaceuticals and Daiichi Sankyo form second collaboration

Eagle Pharmaceuticals' bendamustine hydrochloride product receives orphan drug status

Avraham Pharmaceuticals reports interim data from phase IIb study of ladostigil

Cesca Therapeutics discusses pivotal trial for CLIRST with FDA

FDA approves Kerydin for onychomycosis

Promising phase II and III results for a number of novel oncolytics presented at ASCO

Japanese approval of Jakavi triggers milestone payment to Incyte

InSite Vision plans NDA filing for DexaSite next year

CardioCell initiates phase II trial of allogeneic stem cell therapy for chronic heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...